{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:15:48Z","timestamp":1770326148932,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":2504,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1111\/jth.13178","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T11:16:42Z","timestamp":1446117402000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure"],"prefix":"10.1016","volume":"14","author":[{"given":"J.D.","family":"Douketis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Barty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.A.","family":"Moffat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.A.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Blostein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13178_bb0010","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood-2012-06-415943","article-title":"How I treat anticoagulated patients undergoing an elective procedure or surgery","volume":"120","author":"Spyropoulos","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13178_bb0015","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/ALN.0b013e318289bcba","article-title":"Managing new oral anticoagulants in the perioperative and intensive care unit setting","volume":"118","author":"Levy","year":"2013","journal-title":"Anesthesiology"},{"key":"10.1111\/jth.13178_bb0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.acvd.2011.09.001","article-title":"Surgery and invasive procedures in patients on long\u2010term treatment with direct oral anticoagulants: thrombin or factor\u2010Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis","volume":"104","author":"Si\u00e9","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1111\/jth.13178_bb0025","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/bjs.9485","article-title":"Perioperative management of patients on new oral anticoagulants","volume":"101","author":"Lai","year":"2014","journal-title":"Br J Surg"},{"key":"10.1111\/jth.13178_bb0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/ACO.0000000000000100","article-title":"New direct oral anticoagulants in the perioperative setting","volume":"27","author":"Breuer","year":"2014","journal-title":"Curr Opin Anaesthesiol"},{"issue":"2 Suppl.","key":"10.1111\/jth.13178_bb0035","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.13178_bb0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/AAP.0b013e3181c15c70","article-title":"Regional anesthesia in the patient receiving antithrombotic therapy or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence\u2010based guidelines (third edition)","volume":"35","author":"Horlocker","year":"2010","journal-title":"Reg Anesth Pain Med"},{"key":"10.1111\/jth.13178_bb0045","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/EJA.0b013e32833f6f6f","article-title":"Regional anesthesia and antithrombotic agents: recommendations of the European Society of Anesthesiology","volume":"27","author":"Gogarten","year":"2010","journal-title":"Eur J Anesthesiol"},{"issue":"S1","key":"10.1111\/jth.13178_bb0050","doi-asserted-by":"crossref","first-page":"i96","DOI":"10.1093\/bja\/aet401","article-title":"New oral anticoagulants and regional anesthesia","volume":"111","author":"Benzon","year":"2013","journal-title":"Br J Anesth"},{"key":"10.1111\/jth.13178_bb0055","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2011-10-378950","article-title":"How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch","volume":"119","author":"Schulman","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13178_bb0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jth.12096","article-title":"Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants","volume":"11","author":"Garcia","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.21607","article-title":"Laboratory monitoring of new anticoagulants","volume":"85","author":"Castellone","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.13178_bb0070","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate \u2013 a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0075","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1160\/TH13-04-0301","article-title":"The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples","volume":"110","author":"Hapgood","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0080","first-page":"283","article-title":"Comparison of calibrated chromogenic anti\u2010Xa assay and PT tests with LC\u2010MS\/MS for the therapeutic monitoring of patients treated with rivaroxaban","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0085","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jth.12166","article-title":"Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test","volume":"11","author":"Tripodi","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0090","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/jth.12165","article-title":"Which test to use to measure the anticoagulant effect of rivaroxaban: the anti\u2010factor Xa assay","volume":"11","author":"Samama","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/jth.13178_bb0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/jth.12227","article-title":"The role of the laboratory in treatment with new oral anticoagulants","volume":"11","author":"Baglin","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0105","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jth.12308","article-title":"Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross\u2010sectional pharmacodynamic study based on peak and trough plasma levels","volume":"11","author":"Hawes","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0110","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00228-013-1550-4","article-title":"Evaluation of coagulation assays versus LC\u2010MS\/MS for determinations of dabigatran concentrations in plasma","volume":"69","author":"Antovic","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jth.13178_bb0115","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non\u2010vitamin K oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13178_bb0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.thromres.2014.06.016","article-title":"On the monitoring of dabigartan in \u2018real life\u2019 patients with atrial fibrillation","volume":"134","author":"Skeppholm","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13178_bb0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-06-0342","article-title":"Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays","volume":"105","author":"Lindahl","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1373\/clinchem.2012.198788","article-title":"Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories","volume":"59","author":"Helin","year":"2013","journal-title":"Clin Chem"},{"key":"10.1111\/jth.13178_bb0135","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MBC.0000000000000056","article-title":"Dabigatran assessment in patients with acute complications using routine coagulation assays","volume":"25","author":"Stang","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.13178_bb0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.13178_bb0145","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0150","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1309\/AJCPQOD9WFPEYY0H","article-title":"Measuring direct thrombin inhibitors with routine and dedicated coagulation assays. Which assay is helpful?","volume":"138","author":"Curvers","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.13178_bb0155","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jth.12702","article-title":"Determination of dabigatran, rivaroxaban and apixaban by ultra\u2010performance liquid chromatrography \u2013 tandem mass spectrometry (UPLC\u2010MS\/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants","volume":"12","author":"Schmitz","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/CIRCULATIONAHA.115.015688","article-title":"Perioperative management of patients on dabigatran \u2013 a prospective cohort study","volume":"132","author":"Schulman","year":"2015","journal-title":"Circulation"},{"key":"10.1111\/jth.13178_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1111\/jth.13178_bb0170","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","article-title":"Pacemaker or defibrillator surgery without interruption of anticoagulation","volume":"368","author":"Birnie","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13178_bb0175","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1378\/chest.09-2603","article-title":"Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and meta\u2010analysis","volume":"138","author":"Jamula","year":"2010","journal-title":"Chest"},{"key":"10.1111\/jth.13178_bb0180","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.thromres.2014.07.028","article-title":"Reduced\u2010dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial","volume":"134","author":"Schulman","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13178_bb0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11239-014-1125-y","article-title":"Monitoring of dabigatran therapy using Hemoclot\u00ae thrombin inhibitor assay in patients with atrial fibrillation","volume":"39","author":"Samo\u0161","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.13178_bb0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1309\/AJCPGTCEX7K4GXQO","article-title":"Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples","volume":"141","author":"Lind","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.13178_bb0195","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bcp.12366","article-title":"Coagulation assays and plasma fibrinogen concentrations in real\u2010world patients with atrial fibrillation treated with dabigatran","volume":"78","author":"Chin","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.13178_bb0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE\u2010LY Trial (Randomized Evaluation of Long\u2010Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13178_bb0205","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/jth.12823","article-title":"Real\u2010world variability in dabigatran levels in patients with atrial fibrillation","volume":"13","author":"Chan","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1160\/TH13-07-0576","article-title":"Dabigatran monitoring made simple?","volume":"110","author":"Eikelboom","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13178_bb0215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1309\/AJCPRNUMI4PVSJ7Q","article-title":"Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels","volume":"141","author":"Gosselin","year":"2014","journal-title":"Am J Clin Pathol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13178","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13178","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622049169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622049169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13178\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:12:38Z","timestamp":1761534758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622049169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1538783622049169"],"URL":"https:\/\/doi.org\/10.1111\/jth.13178","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}